Navigation Links
Stemedica Enters into Stem Cell Licensing Agreement with Kalbe Farma

San Diego, CA (PRWEB) April 25, 2013

Stemedica Asia PTE, LTD, a wholly owned subsidiary of Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced that the Company has entered into a definitive licensing agreement with the Stem Cell and Cancer Institute, a division of PT Kalbe Farma Tbk. (Kalbe). Under the terms of the Agreement Kalbe shall be the exclusive licensor of Stemedica’s ischemic tolerant adult allogeneic mesenchymal and neural stem cells for use in clinical trials in Indonesia, Philippines and Thailand. The Agreement also provides Kalbe with first rights of refusal for additional countries including Singapore, Malaysia, Vietnam, Brunei, Cambodia, Laos and Myanmar. Kalbe’s Stem Cell and Cancer Institute shall be responsible for organizing and funding clinical trials in Southeast Asia.

Headquartered in Central Jakarta, Indonesia, Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with close to US $6.5 billion in market capitalization as of Q1 2013. Established in 1966, Kalbe has expanded by strategic acquisitions of companies involved in prescription and over-the-counter pharmaceuticals, energy drinks and nutritional products. Kalbe’s Prescription Pharmaceutical Division features a complete product range including the manufacture of generics and licensed drugs. Pharma Metric Labs, a Kalbe company, is an independent Contract Research Organization (CRO) providing global studies in oncology, monoclonal antibodies and stem cells. Kalbe’s packaging and distribution capabilities allow the company to reach over one million outlets with their brands.

Kalbe’s Stem Cell and Cancer Institute was established in 2006 as part of Kalbe’s founder Dr. Boenjamin Setiawan’s belief that stem cells and regenerative medicine represent the future of medicine. According to Dr. Setiawan, “Our scientists and researchers have thoroughly evaluated worldwide stem cell manufacturers. We have chosen to license Stemedica products based upon the quality of their cGMP manufacturing and the unique attributes of their ischemia tolerant stem cells. Their ability to scale production to treat hundreds of thousands of patients from a single tissue donation is in keeping with our objective as a pharmaceutical company: to bring a safe, effective, off-the-shelf solution to millions of people in Southeast Asia suffering from disease.”

Nikolai Tankovich, MD, PhD, President and Chief Medical Officer of Stemedica noted, “We are honored to be associated with a company of Kalbe’s caliber; a company that strictly adheres to the ethical and regulatory guidelines in medicine.”

Addressing the significance of the collaboration, Maynard Howe, PhD, Stemedica’s Vice-Chairman and Chief Executive Officer noted, “Our agreement with Kalbe is in keeping with our corporate strategy of partnering with global and regional pharmaceutical companies that are committed to licensing our multiple stem cell products for use in approved clinical trials. We are extremely pleased to have a strong partner such as Kalbe for Southeast Asia.”

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and myocardial infarct. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.

About PT. Kalbe Farma Tbk.
PT Kalbe Farma Tbk. (“Kalbe”) is one of the largest publicly-listed pharmaceutical companies in Southeast Asia. Kalbe has a broad and strong portfolio of brands in prescription pharmaceuticals (Cefspan, Brainact, Broadced, etc), OTC pharmaceuticals (Woods, Promag, Mixagrip, Komix, etc), ready-to-drink products (Hydro Coco, Extra Joss, Nitros) and nutritional products (Milna, Prenagen, Diabetasol, etc), complemented with a robust distribution arm covering much of the Indonesian archipelago. Since 1991, Kalbe’s shares have been listed on the Indonesia Stock Exchange (IDX: KLBF).

For more information please contact Dave McGuigan at dmcguigan (at) stemedica (dot) com.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Stemedica Issued U.S. Patent For Stem Cell Treatment of Diabetic Retinopathy and Diabetic Optic Neuropathy
2. Stephen Epstein, MD To Head Scientific & Medical Advisory Board For Stemedica’s Cardiology Division
3. Emory Cardiologists Arshed Quyyumi And Javed Butler Join Stemedica Cardiology Division Scientific Advisory Board
4. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
5. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
6. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
7. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
8. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
9. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
10. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
11. Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies
Post Your Comments:
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 27th Annual ... . .   Listeners ... prior to the presentation to download or install any ... available on the website approximately one hour after the ...
(Date:11/25/2015)... The Global Genomics Industry ... and in-depth study on the current state of ... ) , The report provides ... classifications, applications and industry chain structure. The Genomics ... including development trends, competitive landscape analysis, and key ...
(Date:11/24/2015)... Cepheid (NASDAQ: CPHD ) today announced ... conference, and invited investors to participate via webcast. ... December 1, 2015 at 11.00 a.m. Eastern Time ... December 1, 2015 at 11.00 a.m. Eastern Time ... York, NY      Tuesday, December 1, 2015 at ...
Breaking Biology Technology:
(Date:11/20/2015)... November 20, 2015 NXTD ) ... on the growing mobile commerce market and creator of ... Pereira , was recently interviewed on The RedChip ... on this weekend on Bloomberg Europe , Bloomberg ... --> NXTD ) ("NXT-ID" or the "Company"), ...
(Date:11/18/2015)... PHILADELPHIA , Nov. 18, 2015  As new ... in children, doctors and other healthcare providers face challenges ... counsel families and patients. In addition, as more children ... into a patient,s adulthood and old age. ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... -- Paris , qui s,est ... Paris , qui s,est tenu du 17 ... de l,innovation biométrique, a inventé le premier scanner couplé, ... la même surface de balayage. Jusqu,ici, deux scanners étaient ... empreintes digitales. Désormais, un seul scanner est en mesure ...
Breaking Biology News(10 mins):